Okay, so I need to figure out the correct answer for this question about the treatment of single lesion paucibacillary leprosy. Let me start by recalling what I know about leprosy classifications and treatments.

First, leprosy is classified into paucibacillary (PB) and multibacillary (MB) based on the number of lesions and bacillary load. PB is typically for patients with fewer lesions, usually five or less, and a negative slit-skin smear. MB is for more than five lesions or a positive smear.

The treatment regimens are managed by the World Health Organization (WHO). For PB leprosy, the standard regimen is a combination of rifampicin and dapsone. I remember that rifampicin is a bactericidal drug, and dapsone is bacteriostatic. They are given for six months. Wait, but sometimes there's also a third drug? No, maybe for MB, but for PB it's just the two. Let me confirm that. Yes, WHO recommends a six-month course of monthly doses of rifampicin and dapsone for PB. So the answer should be that the treatment is a six-month regimen of these two drugs.

Looking at the options, if the correct answer is C, then I need to check the options. But since the user hasn't provided the options, I have to assume based on standard knowledge. Common distractors might include incorrect drugs, wrong duration, or adding unnecessary medications like clofazimine (which is used in MB). Also, maybe someone might confuse the duration with 12 months, which is for MB. So the correct answer is the combination of rifampicin and dapsone for six months. Let me structure the explanation accordingly.

**Core Concept**
The treatment of paucibacillary (PB) leprosy (fewer than five skin lesions, negative slit-smear) involves a short-course multidrug therapy (MDT) to eradicate *Mycobacterium leprae*. The World Health Organization (WHO) protocol for PB leprosy includes rifampicin and dapsone administered monthly for six months.

**Why the Correct Answer is Right**
Rifampicin is a potent bactericidal drug that inhibits bacterial RNA synthesis by targeting RNA polymerase, while dapsone acts as a bacteriostatic agent by disrupting folic acid synthesis. This combination prevents resistance and ensures complete clearance of *M. leprae*. The six-month regimen is sufficient for PB leprosy due to its limited bacillary load and fewer lesions.

**Why Each Wrong Option is Incorrect**
**Option A:** Incorrect if it suggests monotherapy (e.g., dapsone alone) or shorter duration, as monotherapy promotes resistance.
**Option B:** Incorrect if it includes clofazimine (used only in multibacillary leprosy) or extends the duration to 12 months (MB regimen).
**Option D:** Incorrect if it proposes non-WHO-approved drugs or dosing intervals (e.g., daily instead of monthly).

**Clinical Pearl / High-Yield Fact**
Never prescribe monotherapy for leprosy! Always use WHO-recommended MDT: **6 months for PB (rifampicin + dapsone)** and **12 months for MB (

✓ Correct Answer: D. Rifampicin, ofloxacin and minocycline